BlackRock Fund Advisors’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

BlackRock Fund Advisors’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$127K	Sell	44,002 -290,601	-87%	-$1.03M	﹤0.01%	3543
2016 Q3	$1.97M	Buy	334,603 +18,881	+6%	+$66.2K	﹤0.01%	3161
2016 Q2	$947K	Sell	315,722 -334,982	-51%	-$1.38M	﹤0.01%	3267
2016 Q1	$3.49M	Buy	650,704 +5,194	+0.8%	+$32.8K	﹤0.01%	2914
2015 Q4	$7.66M	Buy	645,510 +252,794	+64%	+$2.89M	﹤0.01%	2599
2015 Q3	$3.22M	Sell	392,716 -4,468	-1%	-$51.6K	﹤0.01%	2990
2015 Q2	$5.54M	Buy	397,184 +292,195	+278%	+$5.36M	﹤0.01%	2864
2015 Q1	$2.52M	Buy	104,989 +1,805	+2%	+$40.6K	﹤0.01%	3088
2014 Q4	$1.7M	Buy	103,184 +14,715	+17%	+$170K	﹤0.01%	3179
2014 Q3	$1.13M	Buy	88,469 +568	+0.6%	+$8.56K	﹤0.01%	3185
2014 Q2	$1.98M	Sell	87,901 -8,723	-9%	-$158K	﹤0.01%	3128
2014 Q1	$2.73M	Buy	+96,624	New	+$3.59M	﹤0.01%	3090

Other funds holding DRNA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

BlackRock Fund Advisors's DRNA Position: Q4 2016 in Review

BlackRock Fund Advisors reduced its Dicerna Pharmaceuticals, Inc. (DRNA) stake by 87% in Q4 2016, selling an estimated $1.03M and leaving 44,002 shares worth $127K. The position accounts for ﹤0.01% of the portfolio, ranked #3543.

BlackRock Fund Advisors first reported a position in DRNA in Q1 2014 and has held it in 12 quarters since. The position peaked at $7.66M in Q4 2015. 50 funds tracked by Wall St. Rank hold DRNA as of Q4 2016.

BlackRock Fund Advisors held 44,002 shares of Dicerna Pharmaceuticals, Inc. worth $127K as of Q4 2016.
BlackRock Fund Advisors sold 290,601 Dicerna Pharmaceuticals, Inc. shares in Q4 2016, an estimated $1.03M.
Dicerna Pharmaceuticals, Inc. made up ﹤0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #3543 holding.
BlackRock Fund Advisors first reported a position in Dicerna Pharmaceuticals, Inc. in Q1 2014 and has held it in 12 quarters since.
BlackRock Fund Advisors's Dicerna Pharmaceuticals, Inc. position peaked at $7.66M in Q4 2015.
50 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.